372527Department of Clinical Medicine, Weifang Medical University, Weifang, Shandong, China.
71107Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211064719. doi: 10.1177/15330338211064719.
The objective of this retrospective study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost radiotherapy for early breast cancer patients undergoing breast-conserving surgery. A total of 185 women with early breast cancer undergoing breast-conserving surgery were retrospectively divided into hypofractionated simultaneous integrated boost group and conventional fractionation group. Hypofractionated simultaneous integrated boost included 104 patients and the dose of whole-breast radiation reached 42.56 Gy in 16 fractions and simultaneously tumor bed boost to 48 Gy in 16 fractions, which course of radiotherapy was 22 days. The 81 patients of the conventional fractionation group received whole breast radiation to 50 Gy in 25 fractions and followed by tumor bed boost to 10 Gy in 5 fractions, which course of radiotherapy was 40 days. Clinical information including patients' characteristics, skin toxicity, myelosuppression, radiation pneumonia, and cosmetic effects was recorded to analyze the influence of age, chemotherapy, position, and breast volume on the results of radiotherapy. Hypofractionated simultaneous integrated boost group had no case of recurrence after a median follow-up of 25.6 months (9-47 months)) as compared with 2 after a median follow-up of 33.4 months (25-45 months) in the conventional fractionation group. The 2 groups had similar results in skin toxicity, cosmetic outcomes, and radiation pneumonia. In terms of myelosuppression, grade 1, grade 2, and grade 3 of myelosuppression in the hypofractionated simultaneous integrated boost group accounted for 16.7%, 12.3%, and 3.5% as compared with 30.0%, 21.1%, and 12.3% of the conventional fractionation group, respectively ( = .000). HF-SIB RT is a considerable option in patients after breast-conserving surgery with a lower degree of myelosuppression and shorter treatment time.
本回顾性研究旨在评估保乳术后早期乳腺癌患者接受 Hypofractionated 同时整合boost 放疗的疗效和安全性。共有 185 例接受保乳手术的早期乳腺癌患者回顾性分为 Hypofractionated 同时整合 boost 组和常规分割组。Hypofractionated 同时整合 boost 组包括 104 例患者，全乳照射剂量达到 42.56Gy，共 16 次，同时肿瘤床 boost 至 48Gy，共 16 次，放疗疗程为 22 天。常规分割组 81 例患者接受全乳照射 50Gy，共 25 次，随后肿瘤床 boost 至 10Gy，共 5 次，放疗疗程为 40 天。记录了包括患者特征、皮肤毒性、骨髓抑制、放射性肺炎和美容效果在内的临床信息，以分析年龄、化疗、体位和乳房体积对放疗结果的影响。Hypofractionated 同时整合 boost 组在中位随访 25.6 个月（9-47 个月）后无复发病例，而常规分割组在中位随访 33.4 个月（25-45 个月）后有 2 例复发。两组在皮肤毒性、美容效果和放射性肺炎方面结果相似。在骨髓抑制方面，Hypofractionated 同时整合 boost 组的骨髓抑制 1 级、2 级和 3 级分别占 16.7%、12.3%和 3.5%，而常规分割组分别占 30.0%、21.1%和 12.3%（ = .000）。HF-SIB RT 是保乳术后患者的一种较好选择，具有较低的骨髓抑制程度和较短的治疗时间。
